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Endocrine aspects of ovarian cancer have been remarkably
neglected in comparison with the huge research effort
directed at the treatment of this condition with chemo-
therapy. The presence in ovarian cancer cells of receptors
for oestrogen and progesterone (Holt et al., 1979; Rowland
et al., 1985; Sutton et al., 1986), and for androgens (Hamilton
et al., 1981), combined with the ability of these cells to
synthesise steroid hormones (Heinonen et al., 1982; Backstrom
et al., 1983), suggests that hormonal manoeuvres may be
useful in the treatment of this condition.
Objective responses to anti-oestrogen therapy have been
observed in advanced ovarian cancer by a number of
workers (Myers et al., 1981; Schwartz et al., 1982; Pagel et
al., 1983; Campbell et al., 1984; Hamerlynck et al., 1985).
However, the true value of this form of treatment remains
unclear, since several studies have shown apparently
negligible activity (Rowland et al., 1985; Shirey et al., 1985;
Slevin et al., 1986). Heterogeneity of the patient population,
especially with respect to factors such as performance status,
oestrogen and progestogen receptor status and drug
absorption (secondary to gastrointestinal dysfunction), may
explain the varying response rates observed, which range
from 0% (Rowland et al., 1985; Shirey et al., 1985; Slevin et
al., 1986) to 28% (Pagel et al., 1983).
In breast cancer response to tamoxifen often requires
many weeks of treatment. This has been partially attributed
to the pharmacokinetic behaviour of tamoxifen since plateau
concentrations of the drug may only be achieved after
several weeks of treatment with the standard oral regime of
10-20mgbd (Wilkinson et al., 1982). In advanced ovarian
cancer treated with tamoxifen progression of disease has
commonly occurred early (within 3 months) (Slevin et al.,
1986). Although the concentration of tamoxifen required for
therapeutic effect is unknown it is tempting to speculate that
in some patients progression has occurred before adequate
drug levels are achieved.
In order to overcome this possibility, and thus permit a
more adequate evaluation of the activity of tamoxifen we
have treated patients with advanced ovarian cancer with a
schedule of tamoxifen including a loading dose in an attempt
to achieve therapeutic drug levels promptly. Such a regimen
has been shown to produce stable plasma levels of tamoxifen
in patients with breast cancer within 24h (Wilkinson et al.,
1982).
Fifty-three patients with stage III or IV ovarian cancer
who had failed to respond, or who had relapsed following
cytotoxic chemotherapy, were studied. All patients had histo-
logically proven diagnosis of ovarian carcinoma, and all had
measurable disease. Patients had an estimated life expectancy
of at least 3 months. No patient had evidence of bowel
obstruction. Patient characteristics are shown in Table I.
Tamoxifen was given as a loading dose of lOOmgm-2 in 4
divided doses over 24h, followed by a maintenance dose of
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Table I Patient details
Mean age - 61.3 years (range 45-76)
Stage III - 30
IV - 23
Median Karnofsky
performance status 80% (range 40-100%)
Previous treatment - Single alkylating agent - 17
- Single agent platinum - 2
- High dose cyclophosphamide
plus cis-platinum - 3
- Two regimens - 30
- No treatment - I
20mg twice daily. Treatment was administered continuously
until there was unequivocal evidence of progressive disease.
Response was assessed by standard criteria (Miller et al.,
1981).
Fifty-one patients were assessable for response (one was
lost to follow up and one received only 2 weeks treatment
before withdrawing from study). Fifty patients (98% of
assessable patients) experienced progression of disease. In 42
patients progression was noted within 3 months of
commencing treatment. In 5 patients progression occurred
after 4 months of treatment. Median time to progression was
2 months. One patient achieved a partial remission lasting 3
months. Median duration of survival from commencing
tamoxifen was 4 months (range 1-16 months). Three patients
experienced sweating and pruritis while on tamoxifen. There
were no other significant toxicities recorded, and the loading
dose was tolerated without problems.
Despite occasional dramatic responses to anti-oestrogen
therapy (and evidence of activity in vitro (Runge et al.,
1986)), the overall level of activity of this hormonal
manoeuvre is low. Table II summarises the major studies of
tamoxifen treatment in ovarian cancer. Of 229 patients
treated only 3 complete (clinical) remissions and 15 partial
remissions have been observed. Duration of remissions has
been short. Despite the fact that the loading dose schedule in
the present study produces stable plasma levels within 24h it
has not resulted in an improvement in response rate
compared with a previous study from the same group (Slevin
et al., 1986).
The contribution of tamoxifen to the 'static disease' state
seen in a number of patients is unclear, particularly in a
disease which may pursue an indolent course in its later
stages. The significance of stable disease observed during
tamoxifen treatment can only be evaluated in the setting of a
controlled trial.
We conclude that evidence for substantial activity of
tamoxifen in ovarian cancer has previously been overstated,
and that the true activity of this treatment is minimal.
Nevertheless, the frequent occurrence of sex hormone
receptors in ovarian cancer cells should continue to stimulate
investigation of other hormonal manoeuvres in this disease.
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Table II Previously reported studies of tamoxifen in refractory ovarian cancer
Load
Author Previously Dose dose
(ref.) Patients treated mgday 1 YIN Response Comments
Myers et al. 3 3 20-40 N 1 PR 1 CR in patient
(1981) also on MPA.
Pagel et al. 29 29 NSS N 1 CR Median duration
(1983) 7PR of response 3/12
6/8 responsers
oestrogen receptor
positive.
12/29 - stable.
Hamerlynck et al. 36 36 40 N 2PR 7/36 - stable.
(1985)
Landoni et al. 19 11 40 N None 7/19 stable.
(1983)
Campbell et al. 22 22 40 N 2CR Median duration
(1984) 3PR of response 5/12
7 patients
stable.
Schwartz et al. 13 13 20 N 1 PR 4/13 - stable.
(1982)
Rowland et al. 9 9 20 N None Poor performance
(1985) status patients.
Slevin et al. 22 22 40 N None 1/22 - stable.
(1986)
Shirey et al. 23 23 20-40 N None 19/23 - stable.
(1985) (median 17/52)
Present study 53 52 40 Y 1PR
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